

=====

Analyzing ticker: UNH

Ticker will be evaluated for day trading or  
swing trading.

=====

Part 1 - Pull Single Stock from API

=====

Part 2 - Extract / Convert Transcript / Data

=====

Earnings Call Transcript = Token count: 10450  
Earnings Call Transcript = Token count: 4888

Good morning, and welcome to UnitedHealth Group Fourth Quarter and Full Year 2024 Earnings Conference Call. A question-and-answer session will follow UnitedHealth Group's prepared remarks. As a reminder, this call is being recorded. Here are some important introductory information. This call contains forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. A description of some of the risks and uncertainties can be found in the reports that we file with the Securities and Exchange Commission, including the cautionary statements included in our current and periodic filings. This call will also reference non-GAAP amounts. A reconciliation of the non-GAAP to GAAP amount is available on the financial and earnings reports section of the company's investor relations page at [www.unitedhealthgroup.com](http://www.unitedhealthgroup.com). Information presented on this call is contained in the earnings release we issued this morning and in our form 8-K dated January 16, 2025, which may be accessed from the Investor Relations page of the company's website. I will now turn the conference over to the Chief Executive Officer of UnitedHealth Group, Andrew Witty.

Jennifer, thank you very much, and good morning, everyone. I'd like to start by expressing a sincere thank you from my colleagues and from me for the overwhelming expressions of condolence and support following the murder of our friend, Brian Thompson. Many of you knew Brian personally. You knew how much he meant to all of us and how he devoted his time to helping make the health system work better for all of the people we're privileged to serve. He would dive in with passion and caring to find solutions to improve experiences, whether for an individual consumer, an employer or a public health agency. Right now, there are 400,000 nurses, doctors, case workers, customer service specialists, pharmacists, technologists and so many others in this organization, who share that commitment and are determined to advance that work. The task in front of us, all of us, healthcare providers, payers, employers, drug companies and policymakers is to continue improving quality and health outcomes for individuals and their families, while lowering costs for everyone. We need to build on the unique foundational strengths of healthcare in America and address the areas we can make work better. Among those strengths, world-leading innovation, the U.S. has developed the most advanced clinical approaches and patient-centered care at a pace not seen anywhere else. It's why, if provided with the option, people from all over the world come here to seek care for the most complex conditions. Yet, the health system needs to function better. Through decades of federal and state policymaking and private-sector innovation, we have a variety of program structures and processes. There are strong merits to that variety as they can be more tailored to meet the specific needs of individuals at various stages of life and health status and provide extra help for those who need it. It avoids a one-size-fits-all approach, but it needs to be less confusing, less complex and less costly. America faces the same fundamental healthcare dynamic as the rest of the world. The resources available to pay for healthcare are limited, while demand for healthcare is unlimited. Every society wrestles with that issue and approaches it in various ways. We have incredible opportunities here to improve system performance both from a care and a cost perspective, while building upon the foundational strengths I just mentioned. The mission of this company, why we exist, is to improve this system for everybody and help people live healthier lives. That means getting more people into high-quality value-based care and keeping them healthy in the first place, so fewer Americans find themselves with a chronic and, in many cases, preventable disease. It means continuing to invest in programs like Medicare Advantage, which by providing coordinated care to seniors is proven to deliver better health outcomes at lower cost to consumers and taxpayers compared to fee-for-service Medicare. Seniors recognize that value, which is why the majority of them choose Medicare Advantage. It

means making healthcare easier to navigate. We're enhancing digital tools for consumers, harnessing data and using AI so they can find the best value care option and decide what is best for themselves and their families. People's health interaction should be as intuitive and seamless as every other aspect of their lives: banking, shopping, streaming. This past year, we saw an extraordinary increase in the use of these modern channels. We know there is still a large gap there, and we intend to keep at it until it is closed. It means making coverage and cost easier to understand. Just one example where we already have advanced plans, we're eager to work with policy leaders to use standardization and technology to speed up turnaround times for approval of procedures and services for Medicare Advantage patients and to materially reduce the overall number of prior authorizations used for certain MA services. Some of this work we can do on our own, and we're doing it, but we're encouraged also by industry and policymaker interest in solving for this particular friction across the whole system. Ultimately, improving healthcare means addressing the root cause of healthcare costs. Fundamentally, healthcare costs more in the U.S., because the price of a single procedure, visit or prescription is higher here than it is in other countries. The core fact is that price, more than utilization, drives system costs higher. Tackling that problem will require all parts of the system and policymakers to come together. Yet, there are participants in the system who benefit from these high prices, lower-cost equivalent quality sites of service, for example, can be good for consumers and patients, but threaten revenue streams for organizations that depend on charging more for care. Another example is the persistently high cost of drugs in the U.S., leaving American consumers, employers and public agencies to pay disproportionately more than people in other countries. Just look at GLP-1 prices. One drug, which costs \$900 in the U.S., costs about a tenth of that in Europe. Pharmacy benefit managers play a vital role in holding those prices down, which is why drug companies and their allies have spent the past several years attacking them. Optum Rx alone delivers many tens of billions of dollars in savings annually versus the pricing set by the manufacturers, including on the GLP-1s. That sharply reduces the gap versus other countries, but even then prices in the U.S. are still multiples of what the rest of the world pays for the same drugs. Last year, our PBM passed through more than 98% of the rebate discounts we negotiated with drug companies to our clients. While we offer customers 100% pass-through options, a small number have historically elected other models. We're committed to fully phasing out those remaining arrangements so that 100% of rebates will go to customers by 2028 at the latest. We will continue to encourage all of our clients to fully pass these savings directly to patients at the point of sale, as we already do for all of the people we serve in our fully insured employer offerings. This will help make more transparent who is really responsible for drug pricing in this country, the drug companies themselves. Healthcare in every country is complex and the solutions are not simple, but you should expect this company to continue to work at it, finding what is needed, developing solutions, bringing those solutions to scale, making a positive impact on the lives of millions of people. We deliver on our commitments to the people we serve, including our investors. Even in highly challenging periods like 2024, our results bear out that we find a way, even if it's not always how we may have initially envisioned the path. Among some of the formidable challenges we navigated over the course of the year were the first year of the three-year CMS Medicare rate cuts, the effects of the state-driven Medicaid member redeterminations, and the Change Healthcare cyberattack. Our people found a way to deliver solidly within the range we first offered back in November of 2023, all while improving patient and consumer health outcomes and experiences, focusing on quality and expanding upon our potential to help make the health system work better for everyone. We're invigorated by the path ahead. There are so many areas that can be enhanced, reworked, reengineered or even scrapped to make the health system work better as we know it needs to. That is both our responsibility and it's our passion. We begin 2025 with a strong outlook for the year as we continue to deliver on our commitments and excel for those we serve in all of our key growth pillars. Now, John will walk you through this performance in a little more detail.

Thank you, Andrew. And I'll add my deep gratitude for the enormous outpouring of support over the past few weeks. Brian helped build this company and forged deep trusted relationships for over 20 years, and the positive impact he had on people will be felt for years to come. This morning, I'll discuss both 2024 results and our performance expectations for '25, including some of what we had planned to discuss with you in December. 2024 revenues of over \$400 billion and adjusted earnings per share of \$27.66 were well within the outlook ranges we set out over a year ago. To be sure, things played out differently than initially anticipated, but it is an enduring trait of this enterprise that we deliver on our commitments to the people we serve and to you, even amid unforeseen circumstances. Over the course of '24, we undertook initiatives and made investments to strengthen us for the future, initiatives to improve consumer experience and bring new innovations to market more quickly, drive the most compelling ways to further our mission to help make the health system work better for everyone, and continue to optimize and refine our offerings and business portfolio to enhance future growth potential, whether that meant moving into new opportunities, reconfiguring or moving out of areas that contributed historically but may no longer be core, all with an eye to unlocking value. We know you have a number of questions that we were not able to discuss last month. So, today, I'll start by stepping through a couple you have indicated are top of mind. The first one is, why our '24

medical care ratio was 150 basis points above our original outlook? It's important to frame up the challenges of '24 to offer some perspectives on the commitment and response of our people. Compared to the midpoint of the care ratio range we stepped out with over a year ago, that alone created a nearly \$5 billion gap we needed to overcome and that's before we get to the nearly \$1 billion in business disruption impact due to the cyberattack. So, we start with about \$6 billion in unanticipated impacts just from these two examples, in addition to managing through the already known multi-billion dollar impact of the Medicare rate cuts, as we sought to preserve as much benefit stability for seniors as possible. Regarding the elements impacting our '24 care ratio, we've spoken about the key factors on prior earnings calls, so no surprises here. The first comprise about 70% of the total impact and are comparable in magnitude to each other. First, the mix of people served. We ended up with a different profile of consumer than expected. This is because of one factor. We didn't grow as anticipated due to the unusual Medicare Advantage benefit designs in the marketplace in '24. Next, the timing mismatch between the health status of the remaining people being served by Medicaid and lagging state rate updates. Then, there were the costs related to the cyberattack and our South America business impacts. The remaining two elements comprise about 30% of the impact and are evenly split. These include a more rapid-than-expected acceleration in the prescribing of certain high-cost medications as drug companies took early advantage of the Inflation Reduction Act, and an aggressive upshift in hospital coding intensity. This is incorporated into our outlook even as we work to get it back in line. Those are the '24 care ratio elements. Next question, given all that, are we confident in the adequacy of our pricing for '25? The answer is yes, and here's why. To start, for '25, the outlook we shared in December incorporates a view of care activity commensurate with what we saw in '24, even the care activity we experienced as we exited the year. I'll break that down with some business line perspectives. In Medicaid, we see the gap between people's health status and state rates narrowing over the course of the year. Our outlook assumes a measured pacing of that process. Actions to date, including the important January 1 renewal cycle, support this view. In commercial, pricing for '25 is appropriately capturing the care activity we are seeing. This is evidenced by growth heavily weighted towards self-funded offerings. We will continue our disciplined approach. In Medicare, we had strong AEP results, which included winning back people we had served previously and near-record retention. These are a direct result of our long history of offering sustainable benefits for seniors. With strong retention and the many returning consumers, we start the year with highly informed insights into the care needs of the people we will be serving. In addition, this year, we have seen a notable uptake of our more managed offerings; think HMO style, which provides strong value for consumers, effective care tools for doctors and more predictable performance. We expect a '25 full-year medical care ratio of 86.5%, plus or minus 50 basis points, 100 basis points above the '24 result. In addition to factors discussed earlier, the increase is driven by IRA impacts, the second year of the Medicare funding cuts, a continued mix shift toward public sector offerings, and a respectful view of care activity. Our '24 operating cost ratio improved about 150 basis points over the prior year. Roughly half of the change was driven by contributions from the business portfolio initiatives mentioned earlier. The other half was due to accelerating our efforts to realize operating efficiencies, even as we improve consumer experiences. Some of these advances are a result of the very early stage impacts we are beginning to realize from AI-driven initiatives to help our customer service representatives respond to consumers' needs more effectively and quickly. And we see continuing opportunities both in the near-term, with operating costs for '25 improving still further, and well beyond, given the rapidly expanding scope and impact of these initiatives. These actions and the resourcefulness of our people helped deliver upon the objectives set out over one year ago and helped to partially balance the multiple billions of unanticipated impacts.

With that, I'll run through our businesses, offering some key points for each, starting with Optum Health, where revenues grew to about \$105 billion in '24 and are expected to approach \$117 billion in '25. Our care delivery business continues to deepen its presence in existing areas, while expanding into new geographies and services. In '25, we expect Optum Health will serve about 5.4 million value-based care patients, growth of 650,000 over '24. While our current position provides a solid footing, it's a small fraction of the hundreds of millions of patients who can ultimately benefit from value-based care. We see value-based care as foundational. It is perhaps the fullest expression of our mission. As Andrew noted, the outdated activities-based fee-for-service system won't help the health system work better for people. Value-based care is outcomes-based, aligning processes, actions and incentives, helping keep people healthy in the first place rather than just seeing them when they are sick. Optum Health is an integrated multi-payer care delivery company, helping to lead the transition to a truly sustainable value-based care system. As we move into '25, we will continue to enhance access and care integration through the home, a much-needed area to help people with their health. More than three quarters of our in-home patient visits result in a primary care visit within 90 days. Medicare Advantage patients with chronic conditions who receive a home care visit have a lower rate of ER visits, fewer in-patient stays, stronger health outcomes and a better experience, all while saving the health system billions. Turning to Optum Rx. Revenues in '24 grew to over \$130 billion and will be about \$146 billion

in '25. Our pharmacy benefits management team again had customer retention exceeding 98%, while welcoming a record 750 new clients. Further proof of the value that employers, health plans, and labor unions see in Optum Rx's ability to negotiate lower drug prices for consumers. Optum Rx's pharmacy care services support the entire system in the delivery of clinically-driven pharmacy care, serving the highest need and hardest to reach patients. These offerings include community pharmacies, specialty and infusion drug services, all large, strongly growing areas, with our current presence quite small. Optum Insight revenues were \$19 billion in '24, and in '25, we'll approach \$22 billion, with a backlog of \$35 billion as sales of new products begin to take hold and the customer clearinghouse business continues to rebuild. The solutions offered through Optum Insight and our health technology growth pillar, delivered at scale, will improve consumer experience and payment and claims flows, enable access to the next best action guidance in a doctor's workflow, and help life sciences customers more rapidly bring innovations to market. And there will be much more to follow. Shifting to UnitedHealthcare. Full-year revenues in '24 approached \$300 billion, and for '25, we'll approach \$340 billion as we grow to serve upwards of an additional 1.9 million people balanced across both the commercial and public sectors. Within our domestic commercial offerings, we grew to serve 2.4 million more people in '24 and expect to continue to grow strongly in '25, especially in our self-funded offerings, which serve some of the most sophisticated buyers of healthcare, large employers. The fact that so many more people are choosing UnitedHealthcare is a direct result of our bringing much-needed innovation to these more mature markets through consumer-centric offerings. As noted earlier, UnitedHealthcare's '24 Medicare Advantage growth was impacted by the unusual benefit designs in the market. Our focus has always been on providing consumer stability and sustainable value, a factor that has built confidence and trust over the long-term. As a result, in '25, we expect growth of up to 800,000 people in individual, group and special needs offerings. And the growth outlook for the years ahead remains strong, with nearly half of American seniors still in outdated Medicare fee-for-service offerings, which provide less value to them and cost taxpayers more. In Medicaid, we expect to serve more people in '25 with redetermination activities now concluded. UnitedHealthcare's value proposition is resonating with state customers, consumers and provider partners, and we are participating in a substantial number of expansion proposals. Most recently, we were honored to have been awarded a new opportunity in Georgia. Our growing businesses support and are supported by substantial financial capacities and a strong balance sheet. In '24, we deployed nearly \$17 billion in growth capital to help build for the future, further strengthening our capabilities to serve more people more comprehensively. We also returned over \$16 billion to shareholders through dividends and share repurchase. In '25, we expect cash flow from operations will approach \$33 billion or 1.2 times net income. We will continue to deploy growth capital and remain committed to returning to shareholders as outlined in December. Our growth capital deployment efforts delivered their greatest benefits over the course of two, four, or even six years, and as new capabilities are scaled and deployed across the enterprise and beyond. To summarize, our strong start to the year reinforces the growth objectives we shared last month and is underpinned by the broad growth drivers, operational excellence and strategic capital deployment you have come to expect from us. Now, I'll turn it back to Andrew. John, thank you. The strength of this organization lies in the resilience of our people and the fundamental belief that there is no higher calling than helping other people and nothing more vital to the human condition than healthcare. Looking ahead to 2025 and beyond, we're confident in our ability to continue to add value to the health system through our focus on value-based care and consumer-oriented efforts to help build the health system America deserves. And that's also why we remain solidly committed to our long-term 13% to 16% growth objective, a goal that reflects both the opportunities and the capabilities that we have. And now, operator, we'll open it up for questions.

The floor is now open for questions. We'll go first to A.J. Rice with UBS.

Hello, everybody. I appreciate the kind words about Brian. He is missed by all of us. To focus on the comments regarding cost trends and the MLR, there was some variance in the fourth quarter compared to consensus expectations. It was likely a bit more significant than we originally thought. The cost items you've mentioned seem to be consistent with what we've observed throughout the year. Did anything change regarding the intensity of these trends? Were there any unusual items that affected the results? It appears that you're still confident in your MLR outlook for '25, so did anything in the fourth quarter alter your perspective on '25?

A.J., thanks so much for your question. I'm going to ask John in a sec to obviously go much deeper in response to your question, but just to the last part of your question, yeah, you're totally right, nothing we saw there that changes our view of '25. We feel very good about how we priced into '25. We feel really good about how the mix has come in, in terms of that growth. That's a huge difference to '24, and we really didn't see anything in Q4 that we believe represents a challenge to that view going to '25, but I'd love John to go deeper for you on the Q.

Good morning, A.J. Regarding the items we discussed during the third quarter call, the hospital coding intensity and specialty prescribing trends are consistent with what we observed in the third quarter as they carried over into the fourth. We are not witnessing acceleration in these areas; rather, we are seeing stabilization at the levels we had seen previously, and we expect this to continue. The specialty prescribing trends were something we had predicted in our '25 outlook, which moved faster in '24 than anticipated. However, we feel positive about the levels we are observing now, as they align with our expectations for '25. The coding intensity is also holding at the levels we anticipated. Looking at the fourth quarter, there are a couple of points I want to highlight. First, the overall move we experienced is primarily attributed to seasonal factors, such as typical seasonal effects and normal deductible wear-offs. The sequential movement is similar to what we saw from the third to the fourth quarter last year. I would estimate around 80 to 90 basis points of this sequential move relates to revenue effects, including group MA refunds stemming from our strong performance throughout the year. This would fall into the non-recurring revenue category. Additionally, the impact from flu and RSV seasonal effects was about 50 to 60 basis points, which is in line with what we normally expect. The remainder of the moves can be attributed to expected seasonal impacts, particularly those related to revenue effects. Thank you.

Great. Thanks so much, John, and thanks again, A.J., for your question. Next question, please.

We'll go next to Josh Raskin with Nephrion.

Hi, thanks. A question on the Optum Health segment. I guess, and I apologize if I missed this, but did you comment on the change in the consumers? I know you talked about portfolio changes and things like that, but the consumer count dropped about 4 million. And then, sort of a noticeable drop in margins. And I'm wondering if some of that is related to the MA rebates that you just mentioned in terms of the impact on the UHC side as

=====  
Part 3 - DSPy - Financial Tools and Metrics  
=====

===== EARNINGS CALL ANALYSIS RESULTS =====

Revenue: UnitedHealth Group reported 2024 revenues of over \$400 billion and adjusted earnings per share of \$27.66. Optum Health's revenues grew to about \$105 billion in 2024 and are expected to approach \$117 billion in 2025. Optum Rx's revenues in 2024 grew to over \$130 billion and will be about \$146 billion in 2025. Optum Insight revenues were \$19 billion in 2024, and in 2025, they will approach \$22 billion. UnitedHealthcare's full-year revenues in 2024 approached \$300 billion, and for 2025, they will approach \$340 billion. Guidance: UnitedHealth Group expects a 2025 full-year medical care ratio of 86.5%, plus or minus 50 basis points, 100 basis points above the 2024 result. The company expects cash flow from operations to approach \$33 billion or 1.2 times net income in 2025. Optum Health is expected to serve about 5.4 million value-based care patients in 2025, growth of 650,000 over 2024. UnitedHealthcare expects growth of up to 800,000 people in individual, group, and special needs offerings in 2025.

Sentiment: 0.6

Volatility: Moderate

Financial Metrics: UnitedHealth Group reported 2024 revenues of over \$400 billion and adjusted earnings per share of \$27.66. Optum Health's revenues grew to about \$105 billion in 2024 and are expected to approach \$117 billion in 2025. Optum Rx's revenues in 2024 grew to over \$130 billion and will be about \$146 billion in 2025. Optum Insight revenues were \$19 billion in 2024, and in 2025, they will approach \$22 billion. UnitedHealthcare's full-year revenues in 2024 approached \$300 billion, and for 2025, they will approach \$340 billion.

Challenges: UnitedHealth Group faced several challenges in 2024, including the first year of the three-year CMS Medicare rate cuts, the effects of the state-driven Medicaid member redeterminations, and the Change Healthcare cyberattack. The company also faced challenges related to the mix of people served, the timing mismatch between the health status of the remaining people being served by Medicaid and lagging state rate updates, costs related to the cyberattack, and South America business impacts.

Opportunities: UnitedHealth Group sees opportunities in improving system performance both from a care and a cost perspective. The company aims to get more people into high-quality value-based care and keep them healthy in the first place. It also plans to continue

investing in programs like Medicare Advantage and enhancing digital tools for consumers. The company sees opportunities in making healthcare easier to navigate and making coverage and cost easier to understand.

Management Tone: The management's tone is confident and forward-looking. They express confidence in their ability to continue to add value to the health system through their focus on value-based care and consumer-oriented efforts. They also remain solidly committed to their long-term 13% to 16% growth objective.

=====

Results saved to data/dspy\_processed\_earnings\_call.txt

=====

Part 4 - Best Matching Common Search

=====

Results for query: 'support outpouring volatile unanticipated uncertainty weekly churn medicare advantage rates'

Score: 1.8532

Document 2:

Thank you, Andrew. And I'll add my deep gratitude for the enormous outpouring of support over the past few weeks. Brian helped build this company and forged deep trusted relationships...

Score: 1.2535

Document 3:

Tim Noel, Yeah, thanks for the question, Stephen. As you know, these rates are preliminary at this point in time and won't be finalized until April...

Score: 0.5640

Document 1:

Andrew Witty, Jennifer, thank you very much, and good morning, everyone. I'd like to start by expressing a sincere thank you from my colleagues and from me for the overwhelming expressions of condolence and support following the murder of our friend, Brian Thompson...

Score: 0.0000

Document 0:

Good morning, and welcome to UnitedHealth Group Fourth Quarter and Full Year 2024 Earnings Conference

Score explanation for document 0 with query 'support outpouring volatile unanticipated uncertainty weekly churn medicare advantage rates':

Term: 'support'

- Term frequency: 0
- IDF: 0.6931
- Document length factor: 0.9671
- Score contribution: 0.0000

Term: 'outpouring'

- Term frequency: 0
- IDF: 1.2040
- Document length factor: 0.9671
- Score contribution: 0.0000

Term: 'volatile'

- Term frequency: 0
- IDF: 2.3026

- Document length factor: 0.9671
- Score contribution: 0.0000

Term: 'unanticipated'

- Term frequency: 0
- IDF: 2.3026
- Document length factor: 0.9671
- Score contribution: 0.0000

Term: 'uncertainty'

- Term frequency: 0
- IDF: 2.3026
- Document length factor: 0.9671
- Score contribution: 0.0000

Term: 'weekly'

- Term frequency: 0
- IDF: 2.3026
- Document length factor: 0.9671
- Score contribution: 0.0000

Term: 'churn'

- Term frequency: 0
- IDF: 2.3026
- Document length factor: 0.9671
- Score contribution: 0.0000

Term: 'medicare'

- Term frequency: 0
- IDF: 2.3026
- Document length factor: 0.9671
- Score contribution: 0.0000

Term: 'advantage'

- Term frequency: 0
- IDF: 2.3026
- Document length factor: 0.9671
- Score contribution: 0.0000

Term: 'rates'

- Term frequency: 0
- IDF: 1.2040
- Document length factor: 0.9671
- Score contribution: 0.0000

Total score: 0.0000

---

#### Part 4.1 - Financial Rules Matching

---

Average Daily Volume: 6035528.62

Average True Range (ATR): 29.550607142857153

Relative Volume (RVOL): 0.38602716459324815

Average Intraday Volatility (%): 2.8233284556078324

5-Day Price Momentum (%): 7.084343318176178

Daily Rating Score: 5

Daily Recommendation: True

Latest RSI: 73.19510250035182

Latest 14Day ATR: 29.550607142857153

Latest 28Day ATR: 20.2887

Latest 42Day ATR: 18.76309285714285

Latest VWAP: 505.7545130169558

Swing Trade Rating Score: 5

Swing Trade Recommendation: True

Latest RSI: 73.19510250035182

Latest 14Day ATR: 29.550607142857153

Latest 28Day ATR: 20.2887

Latest 42Day ATR: 18.76309285714285

Latest VWAP: 505.7545130169558

---

#### Part 5.1 - Model Context Protocol

---

#### Available Financial Metrics:

##### Income Statement Metrics:

revenue, costOfRevenue, grossProfit, grossProfitRatio, researchAndDevelopmentExpenses...

##### Balance Sheet Metrics:

cashAndCashEquivalents, shortTermInvestments, cashAndShortTermInvestments, netReceivables, inventory...

##### Cash Flow Metrics:

netIncome, depreciationAndAmortization, deferredIncomeTax, stockBasedCompensation, changeInWorkingCapital...

#### == RATIO ANALYSIS EXAMPLE ==

```
{"metrics": [{"insights": "UNH's gross profit ratio showed modest improvement "
  'in 2022, increasing to 24.09% from 23.60% in 2021. '
  'However, this was followed by a slight decline in '
  '2023 to 23.64%, and a more substantial drop in 2024 '
  'to 22.33%. The consistent decline since 2022 '
  "suggests increased cost pressures in the company's "
  'core operations, possibly due to rising healthcare '
  'costs, changing reimbursement models, or '
  'competitive pricing pressures.',

  'name': 'grossProfitRatio',
  'values': [{"company': 'UNH', 'value': '0.2360', 'year': '2021'},
    {"company": "UNH", "value": "0.2409", "year": "2022"}, 
    {"company": "UNH", "value": "0.2364", "year": "2023"}, 
    {"company": "UNH", 
      "value": "0.2233", 
      "year": "2024"}]}, 

  {"insights": "The operating income ratio improved from 8.40% in "
  '2021 to 8.83% in 2022, remained relatively stable '
  'at 8.80% in 2023, before declining to 8.07% in '
  '2024. This pattern mirrors the gross profit trend '
  'but with a more pronounced drop in 2024, indicating '
  'that operating expenses have increased relative to '}
```

'revenue. This suggests potential challenges in '  
'operational efficiency, possibly due to rising '  
'administrative costs, technology investments, or '  
'integration expenses from acquisitions.',  
'name': 'operatingIncomeRatio',  
'values': [{  
    'company': 'UNH', 'value': '0.0840', 'year': '2021'},  
    {'company': 'UNH', 'value': '0.0883', 'year': '2022'},  
    {'company': 'UNH', 'value': '0.0880', 'year': '2023'},  
    {'company': 'UNH',  
        'value': '0.0807',  
        'year': '2024'}]},  
{'insights': 'The net income ratio shows the most concerning '  
    'trend. After modest improvement to 6.25% in 2022 '  
    'from 6.06% in 2021, and a slight decline to 6.09% '  
    'in 2023, there was a dramatic drop to 3.60% in 2024 '  
    '- a 41% year-over-year decrease. This substantial '  
    'decline suggests significant extraordinary items, '  
    'tax implications, or non-operational expenses that '  
    'have severely impacted the bottom line. The '  
    'disproportionate drop compared to the operating '  
    'income ratio indicates issues beyond core '  
    'operations, possibly including one-time charges, '  
    'restructuring costs, or changes in tax provisions.',  
'name': 'netIncomeRatio',  
'values': [{  
    'company': 'UNH', 'value': '0.0606', 'year': '2021'},  
    {'company': 'UNH', 'value': '0.0625', 'year': '2022'},  
    {'company': 'UNH', 'value': '0.0609', 'year': '2023'},  
    {'company': 'UNH',  
        'value': '0.0360',  
        'year': '2024'}]}],  
'recommendations': '',  
'summary': 'UnitedHealth Group (UNH) has demonstrated generally stable '  
    'profitability metrics from 2021-2023, but experienced notable '  
    'deterioration across all profitability ratios in 2024. Most '  
    'concerning is the significant drop in net income ratio in 2024, '  
    'which fell by approximately 41% compared to 2023, indicating '  
    'potential operational challenges or extraordinary expenses that '  
    'have substantially impacted bottom-line performance.',  
'trends': 'All three profitability metrics show a similar pattern: modest '  
    'improvement from 2021 to 2022, followed by slight declines in '  
    '2023, and then more significant decreases in 2024. However, the '  
    'severity of decline varies substantially, with net income ratio '  
    'showing by far the most dramatic deterioration in 2024. The '  
    'widening gap between operating income and net income ratios in '  
    '2024 suggests increasing non-operational costs or financial '  
    'expenses that are eroding bottom-line performance. The correlation '  
    'between all three metrics declining simultaneously points to '  
    'systemic challenges rather than isolated operational issues.'}

==== TREND ANALYSIS EXAMPLE ===

```
{"metrics": [{"insights": "UnitedHealth Group has shown consistent 'year-over-year revenue growth throughout the 5-year period. The yearly growth rates were: 11.6% (2020-2021), 12.9% (2021-2022), 14.1% (2022-2023), and 8.9% (2023-2024). While growth remained strong in 2024, the rate has somewhat decelerated compared to 2023. The compound annual growth rate (CAGR) for revenue over this period is approximately 11.9%, indicating robust business expansion.",  
"name": "revenue",  
"values": [{"company": "UNH",  
"value": "255,639,000,000",  
"year": "2020"},  
{"company": "UNH",  
"value": "285,273,000,000",  
"year": "2021"},  
{"company": "UNH",  
"value": "322,132,000,000",  
"year": "2022"},  
{"company": "UNH",  
"value": "367,533,000,000",  
"year": "2023"},  
{"company": "UNH",  
"value": "400,278,000,000",  
"year": "2024"}]},  
{"insights": "Net income shows a concerning pattern in the provided data. After steady growth from 2020-2023 (with increases of 12.2%, 16.4%, and 11.2% respectively), there was a significant 35.6% decrease in 2024. Note that the data contains duplicate entries with slight variations for each year, which suggests potential data inconsistencies or adjustments in reporting. Using the first entry for each year, the dramatic drop in 2024 requires further investigation, as it contrasts with the continued revenue growth during the same period.",  
"name": "netIncome",  
"values": [{"company": "UNH",  
"value": "15,403,000,000",  
"year": "2020"},  
 {"company": "UNH",  
"value": "17,285,000,000",  
"year": "2021"},  
 {"company": "UNH",  
"value": "20,120,000,000",  
"year": "2022"},  
 {"company": "UNH",  
"value": "15,403,000,000",  
"year": "2023"},  
 {"company": "UNH",  
"value": "10,900,000,000",  
"year": "2024"}]}]
```

```

        'value': '22,381,000,000',
        'year': '2023'},
        {'company': 'UNH',
        'value': '14,405,000,000',
        'year': '2024'}]]}],
'recommendations': '',
'summary': 'UnitedHealth Group (UNH) has demonstrated strong consistent '
    'revenue growth from 2020 to 2024, with a 56.6% overall increase '
    'during this period. However, net income shows irregular reporting '
    '(duplicate entries for some years) and a concerning decrease in '
    '2024 after steady growth in previous years. The company '
    'maintained solid revenue growth even during the challenging 2024 '
    'period when net income declined significantly.',
'trends': 'UNH demonstrates strong revenue growth throughout the analyzed '
    'period, with annual increases ranging from 8.9% to 14.1%. The '
    'revenue growth accelerated from 2020 through 2023 before slowing '
    'slightly in 2024, though still remaining robust. The net income '
    'trend shows steady growth from 2020 through 2023, with annual '
    'increases between 11-16%, followed by a significant decline in '
    '2024 (35.6% decrease). This divergence between continued revenue '
    'growth and declining net income in 2024 signals potential '
    'profitability challenges, possibly due to increased costs, changes '
    'in reimbursement rates, regulatory impacts, or one-time charges '
    'affecting the bottom line.'}

```

## ==== COMPARATIVE ANALYSIS EXAMPLE ====

```

{'metrics': [{}{'insights': 'UnitedHealth Group maintained a remarkably '
    'consistent net income ratio over the three-year '
    'period, hovering around 6.1%. The company saw a '
    'slight improvement in 2022 with a 0.19 percentage '
    'point increase from 2021, followed by a minor '
    'decline of 0.16 percentage points in 2023. This '
    'stability in profit margins suggests effective cost '
    'management despite potential market challenges and '
    'regulatory pressures in the healthcare industry. '
    "Without Humana's data, we cannot determine how "
    "UNH's performance compares to this direct "
    'competitor in the health insurance sector.',

    'name': 'netIncomeRatio',
    'values': [{}{'company': 'UNH',
        'value': '0.0606 (6.06%)',
        'year': '2021'},
        {'company': 'UNH',
        'value': '0.0625 (6.25%)',
        'year': '2022'},
        {'company': 'UNH',
        'value': '0.0609 (6.09%)',
        'year': '2023'}]
}

```

```
{'company': 'HUM',
 'value': 'No data provided',
 'year': '2021'},
 {'company': 'HUM',
 'value': 'No data provided',
 'year': '2022'},
 {'company': 'HUM',
 'value': 'No data provided',
 'year': '2023']}],
{'insights': 'UnitedHealth Group demonstrated significant and '
 'consistent asset growth over the three-year period. '
 'Assets increased by 15.8% from 2021 to 2022 ($33.5 '
 'billion) and by 11.4% from 2022 to 2023 ($28.0 '
 'billion), resulting in a 29.0% overall growth from '
 '2021 to 2023. This substantial expansion likely '
 'reflects strategic acquisitions, investments in '
 'technology infrastructure, and organic growth. The '
 'consistent upward trajectory suggests UNH is '
 'continuing to strengthen its market position and '
 'operational capacity within the healthcare sector.',
 'name': 'totalAssets',
 'values': [{['company': 'UNH',
 'value': '$212.21 billion',
 'year': '2021'],
 ['company': 'UNH',
 'value': '$245.71 billion',
 'year': '2022'],
 ['company': 'UNH',
 'value': '$273.72 billion',
 'year': '2023'],
 ['company': 'HUM',
 'value': 'No data provided',
 'year': '2021'],
 ['company': 'HUM',
 'value': 'No data provided',
 'year': '2022'],
 ['company': 'HUM',
 'value': 'No data provided',
 'year': '2023']}]],
'recommendations': '',
'summary': 'The analysis examines UnitedHealth Group (UNH) financial '
 'performance from 2021 to 2023, focusing on net income ratio and '
 'total assets. Unfortunately, the comparative analysis with Humana '
 '(HUM) is limited as no data was provided for HUM. UNH '
 'demonstrates stable profitability with a slight increase in 2022 '
 'and a return to 2021 levels in 2023. The company shows '
 'significant asset growth, increasing by approximately 29% over '
 'the three-year period, indicating substantial expansion.',
'trends': 'UnitedHealth Group exhibits two primary trends over the analyzed '
```

```
'period: 1) Remarkable stability in profitability, with the net income ratio remaining within a narrow band between 6.06% and 6.25%, demonstrating consistent operational efficiency despite external market factors; 2) Substantial and steady asset growth, with total assets increasing by approximately $61.5 billion (29.0%) over three years, indicating significant business expansion through both organic growth and potentially strategic acquisitions. The combination of stable profitability with substantial asset growth suggests UNH is effectively managing its expanding operations while maintaining profit discipline.'}
```

== CUSTOM ANALYSIS EXAMPLE ==

```
{'metrics': [{'insights': "UNH has consistently increased its cash reserves from 2020 to 2023, with a 50.3% growth over this period. However, 2024 shows a slight decrease of 0.5% compared to 2023, potentially indicating a shift in cash management strategy or increased capital deployment. The substantial cash position provides a strong liquidity buffer for operations and potential opportunities.",  
'name': 'cashAndCashEquivalents',  
'values': [{  
    'company': 'UNH',  
    'value': '$16.92 billion',  
    'year': '2020'},  
    {  
    'company': 'UNH',  
    'value': '$21.38 billion',  
    'year': '2021'},  
    {  
    'company': 'UNH',  
    'value': '$23.37 billion',  
    'year': '2022'},  
    {  
    'company': 'UNH',  
    'value': '$25.43 billion',  
    'year': '2023'},  
    {  
    'company': 'UNH',  
    'value': '$25.31 billion',  
    'year': '2024']}],  
'insights': "UNH's total debt has grown significantly, with a 77% increase from 2020 to 2024. The most substantial year-over-year increases occurred between 2021-2022 (25.3%) and 2023-2024 (23.0%). This accelerating debt accumulation suggests an aggressive expansion strategy, potentially through acquisitions or capital investments, but also increases financial risk.",  
'name': 'totalDebt',  
'values': [{  
    'company': 'UNH',  
    'value': '$43.47 billion',  
    'year': '2020'}]}
```

```
{'company': 'UNH',
 'value': '$46.00 billion',
 'year': '2021'},
{'company': 'UNH',
 'value': '$57.62 billion',
 'year': '2022'},
{'company': 'UNH',
 'value': '$62.54 billion',
 'year': '2023'},
{'company': 'UNH',
 'value': '$76.90 billion',
 'year': '2024']}],
{'insights': 'Net debt (total debt minus cash) decreased by 7.2% '
 'from 2020 to 2021, indicating improved balance '
 'sheet strength. However, it has since increased '
 'dramatically, with a 94.4% overall increase from '
 '2020 to 2024. The most significant jump occurred '
 'between 2023 and 2024 (39.0%), reflecting that debt '
 'is growing much faster than cash reserves, '
 'potentially signaling higher financial leverage.'},
{'name': 'netDebt',
 'values': [{"company": "UNH",
   "value": "$26.55 billion",
   "year": "2020"},
 {"company": "UNH",
   "value": "$24.63 billion",
   "year": "2021"},
 {"company": "UNH",
   "value": "$34.26 billion",
   "year": "2022"},
 {"company": "UNH",
   "value": "$37.11 billion",
   "year": "2023"},
 {"company": "UNH",
   "value": "$51.59 billion",
   "year": "2024"}]},
{'insights': 'The debt-to-cash ratio improved from 2.57 in 2020 '
 'to 2.15 in 2021, indicating stronger liquidity '
 'relative to debt obligations. However, the ratio '
 'has deteriorated since then, reaching 3.04 in '
 '2024—the highest in the five-year period. This '
 'suggests UNH is taking on more debt without '
 'proportionally increasing its cash reserves, '
 'potentially reducing financial flexibility.'},
{'name': 'Debt-to-Cash Ratio',
 'values': [{"company": "UNH", "value": "2.57", "year": "2020"},
 {"company": "UNH", "value": "2.15", "year": "2021"},
 {"company": "UNH", "value": "2.47", "year": "2022"},
 {"company": "UNH", "value": "2.46", "year": "2023"}]}
```

```
{'company': 'UNH', 'value': '3.04', 'year': '2024'}]]],  
'recommendations': '',  
'summary': 'UnitedHealth Group (UNH) has demonstrated strong cash position '  
    'growth from 2020 to 2024, with cash and cash equivalents '  
    'increasing by approximately 50%. However, total debt has grown at '  
    'a faster rate (77% increase), resulting in significantly higher '  
    'net debt (94% increase). The company maintains sufficient '  
    'liquidity for short-term obligations, but the widening gap '  
    'between cash reserves and total debt suggests an increasingly '  
    'leveraged financial position that warrants monitoring.',  
'trends': 'UNH has maintained strong liquidity with steadily increasing cash '  
    'reserves until 2023, followed by a slight plateau in 2024. '  
    'However, debt is growing at a significantly faster rate than cash '  
    'reserves, especially in the most recent years. The debt-to-cash '  
    'ratio improved initially but has worsened since 2021, reaching its '  
    'highest point in 2024. This divergence between cash growth (50% '  
    'increase) and debt growth (77% increase) over the five-year period '  
    'indicates an increasingly leveraged position. The company appears '  
    'to be financing expansion or strategic initiatives through debt '  
    'while maintaining substantial cash reserves, possibly to preserve '  
    'financial flexibility in an uncertain economic environment.'}
```

---

---

Part 6 - Special Sections for Website

---

---

Part 7 - Backtesting and Evaluation

---

---

Based on the analysis above the ticker UNH is suitable for swing trading due to its volatility over a two week time period.  
Based on the analysis above the ticker UNH is suitable for day trading, due to its daily volatility. Please do so with caution  
Backtesting complete for this run of UNH. The data seems reasonable. However, please evaluate on your own and remember market  
conditions are subject to change and volatility. Invest at your own risk.